C2331
Monoclonal Anti-Carcinoembryonic Antigen antibody produced in mouse
clone C6G9, ascites fluid
Product Name
Monoclonal Anti-Carcinoembryonic Antigen antibody produced in mouse, clone C6G9, ascites fluid
biological source
mouse
conjugate
unconjugated
antibody form
ascites fluid
antibody product type
primary antibodies
clone
C6G9, monoclonal
contains
15 mM sodium azide
species reactivity
human
technique(s)
flow cytometry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:8,000 using human colon carcinoma tissue
western blot: suitable
isotype
IgG1
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... CEACAM5(1048)
Related Categories
Application
Monoclonal Anti-Carcinoembryonic Antigen antibody is suitable for use in immunohistochemistry (1:8,000 using formalin-fixed, paraffin-embedded sections of human colon carcinoma tissue).
Monoclonal Anti-Carcinoembryonic Antigen antibody produced in mouse has been used in western blot analysis and surface plasmon resonance (SPR) based immunoassay.
Biochem/physiol Actions
Carcinoembryonic Antigen (CEA) inhibits tumor growth in colon, hepatoma and prostate cancers.
The antibody reacts specifically with human CEA (CD66e, 180 kDa) from several types of malignant tissue including colorectal, lung and breast tumors. It also stains medullary carcinomas of the thyroid. The product reacts strongly with the cell surface and cytoplasm of malignant glands in colorectal adenocarcinomas. A weak reactivity is seen with normal colon mucosa and occasionally with bile canalicular and pancreatic acinar cells, but not with other tested tissue including term placenta. There is no cross-reactivity with non-specific cross-reacting antigen (NCA) present in granulocytes, using immunoblotting, flow cytometry and immunohistochemical techniques. The antibody recognizes an epitope that is resistant to 30 minute oxidation by 1% sodium periodate solution in routine formalin-fixed and paraffin-embedded tissue sections. Enzymatic predigestion with proteolytic enzymes improves immunohistochemical staining with the antibody.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
Carcinoembryonic Antigen (CEA) is a member of the immunoglobulin superfamily that regulates cellular signaling and adhesion. CEA inhibits cell differentiation and subsequently facilitates tumor growth . Thus, CEA has been implicated in various cancers, including colorectal, lung and breast tumors
Monoclonal Anti-Human Carcinoembryonic Antigen (CEA) reacts specifically with human CEA (CD66e, 180 kDa) from different types of malignant tissues. The antibody detects an epitope which is resistant to 30 minute oxidation by 1% sodium periodate solution in formalin-fixed, paraffin-embedded tissue sections. Enzymatic predigestion with proteolytic enzymes enhances immunohistochemical staining with the antibody.The product reacts with medullary thyroid cancers and also associates with cell surface and cytoplasm of malignant glands in colorectal adenocarcinomas. Additionally, the product reacts weakly with normal colon mucosa and occasionally reacts with bile canalicular and pancreatic acinar cells. However, the antibody does not react with other tested tissue such as term placenta, nor does it bind to non-specific cross-reacting antigen (NCA) in granulocytes.
Monoclonal Anti-Human Carcinoembryonic Antigen (CEA) reacts specifically with human CEA (CD66e, 180 kDa) from different types of malignant tissues. The antibody detects an epitope which is resistant to 30 minute oxidation by 1% sodium periodate solution in formalin-fixed, paraffin-embedded tissue sections. Enzymatic predigestion with proteolytic enzymes enhances immunohistochemical staining with the antibody.The product reacts with medullary thyroid cancers and also associates with cell surface and cytoplasm of malignant glands in colorectal adenocarcinomas. Additionally, the product reacts weakly with normal colon mucosa and occasionally reacts with bile canalicular and pancreatic acinar cells. However, the antibody does not react with other tested tissue such as term placenta, nor does it bind to non-specific cross-reacting antigen (NCA) in granulocytes.
Carcinoembryonic Antigen (CEA) is located on human chromosome 19q13.2.
Immunogen
carcinoembryonic antigen (CEA) isolated from a human colon adenocarcinoma cell line.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
A genetic linkage map of the mouse: current applications and future prospects.
Copeland NG
Science, 262(5130), 57-66 (1993)
Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma
Xu J, et al.
Cellular Physiology and Biochemistry, 45(4), 1631-1640 (2018)
The role of the carcinoembryonic antigen receptor in colorectal cancer progression
Bajenova O, et al.
Journal of integrative oncology., 6(2), 192-192 (2017)
Virna Cortez-Retamozo et al.
Cancer research, 64(8), 2853-2857 (2004-04-17)
Nanobodies are the smallest fragments of naturally occurring single-domain antibodies that have evolved to be fully functional in the absence of a light chain. Nanobodies are strictly monomeric, very stable, and highly soluble entities. We identified a nanobody with subnanomolar
Marta Compte et al.
Oncoimmunology, 3, e28810-e28810 (2014-07-25)
Gene therapy to achieve in vivo secretion of recombinant anti-CD3 x anti-tumor bispecific antibodies in cancer patients is being explored as a strategy to counterbalance rapid renal elimination, thereby sustaining levels of bispecific antibodies in the therapeutic range. Here, we
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service